Fol. Biol. 2007, 53, 37-49
Valproic Acid, a Molecular Lead to Multiple Regulatory Pathways
Valproic acid (2-propyl pentanoic acid) is a drug used for the treatment of epilepsy and bipolar disorder. Although very rare, side effects such as spina bifida and other defects of neural tube closure indicate that valproic acid interferes with developmental regulatory pathways. Recently obtained data show that valproic acid affects cell growth, differentiation, apoptosis and immunogenicity of cultured cancer cells and tumours. Focused studies uncovered the potential of valproic acid to interfere with multiple regulatory mechanisms including histone deacetylases, GSK3 α α and β β, Akt, the ERK pathway, the phosphoinositol pathway, the tricarboxylic acid cycle, GABA, and the OXPHOS system. Valproic acid is emerging as a potential anticancer drug and may also serve as a molecular lead that can help design drugs with more specific and more potent effects on the one side and drugs with wide additive but weaker effects on the other. Valproic acid is thus a powerful molecular tool for better understanding and therapeutic targeting of pathways that regulate the behaviour of cancer cells.
Keywords
Funding
Authors are supported by grants 304/07/0529 and 301/05/0859 from the Czech Science Foundation, and 0021620806 from the Ministry of Education, Youth and Sports of the Czech Republic.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.